Bristol-Myers Squibb, Oncolys complete license agreement for festinavir
Links shared publicly online about this topic.
- 641total visits
Bristol-Myers Squibb, Oncolys complete license agreement for festinavir
Bristol-Myers Squibb Company and Oncolys BioPharma Inc., a privately held biotechnology company based in Japan, announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire exclusive worldwide rights to manufacture, develop and commercialize festinavir, a once-a-day, orally available nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development for HIV.
View full resource at news-medical.net
Tags: HIV, AIDS, STD, Biotech, Bristol-Myers Squibb, News
Most Recently Shared on December 20, 2010 at 6:38 pm By:
HIV/AIDS News: Bristol-Myers Squibb, Oncolys complete license agreement for festinavir: Bristol-Myers Squibb Com... http://bit.ly/ggbWKS
Advertisement
